Clinical Trials

Several clinical trials are currently investigating melanin and skin pigmentation characteristics, targeting conditions such as generalized melanin pigmentation in pulse oximetry assessments, acanthosis nigricans-related hyperpigmentation, and skin laxity. Sponsored by academic and clinical institutions including the University of California San Diego, Huashan Hospital, Srinakharinwirot University, and Mahidol University, these Phase 3 and unclassified protocols are currently recruiting or enrolling by invitation. The interventions evaluated range from spectrophotometric calibration for pulse oximetry to light-emitting diode phototherapy and picosecond laser treatments.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06298422 Enrolling by invitation
Generalised Melanin Pigmentation|Pulse Oximetry
University of California San Diego
2024-04-01 --
NCT06349447 Recruiting
Hyperpigmentation
Yanjun Dan|Huashan Hospital
2024-04-10 Not Applicable
NCT06213987 Recruiting
Acanthosis Nigricans|Hyperpigmentation
Srinakharinwirot University
2024-02-01 Phase 3
NCT06231914 Recruiting
Laxity; Skin
Mahidol University
2023-12-01 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Melanin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Melanin functions as a polymer pigment that absorbs broad-spectrum light and quenches reactive oxygen species, thereby protecting epidermal cells from oxidative damage and radiation-induced stress. This intrinsic photoprotective and light-absorbing capacity directly determines skin pigmentation, providing essential context for managing hyperpigmentation disorders and refining optical measurements in pulse oximetry.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.